The individualized treatment for DLBCL: inadequacies of ESMO guidelines
10.3760/cma.j.issn.1009-9921.2013.09.002
- VernacularTitle:弥漫大B细胞淋巴瘤的个体化治疗:欧洲临床肿瘤协会的推荐及不足
- Author:
Zengjun LI
;
Lugui QIU
- Publication Type:Journal Article
- Keywords:
Lymphoma,large B-cell,diffuse;
Individualized treatment;
European Society for Medical Oncology
- From:
Journal of Leukemia & Lymphoma
2013;22(9):514-516
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma is the most common histology of non-Hodgkin lymphoma and is composed of clinically and pathologically heterogeneous group.The ESMO clinical practice guidelines stratified the diseases according to age,age-adjusted IPI and feasibility of dose-intensified approaches.While the regimens suggested by ESMO are almost the same:six to eight cycles of chemotherapy with CHOP combined with rituximah.This article discussed the inadequacies of the guideline according to the recent clinical and pre-clinical studies and the authors' personal experiences.Four deficiencies are outlined:new prognostic factors are not included for the stratification,no therapy adjustmett was advised according to the response,overload therapy for the very-low risk patient,and insufficient therapy for the young,high-risk patients.
